Cargando…

Is Aducanumab for LMICs? Promises and Challenges

Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA). A substantial proportion of patients with Alzheimer’s disease live in low- and middle-income countries...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gunawardena, Illangage P. C., Retinasamy, Thaarvena, Shaikh, Mohd. Farooq
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615623/ https://www.ncbi.nlm.nih.gov/pubmed/34827546 http://dx.doi.org/10.3390/brainsci11111547

Ejemplares similares

Ethanolic Extract of Orthosiphon stamineus Improves Memory in Scopolamine-Induced Amnesia Model
por: Retinasamy, Thaarvena, et al.
Publicado: (2019)

The Role of High Mobility Group Box 1 (HMGB1) in Neurodegeneration: A Systematic Review
por: Ikram, Fathimath Zaha, et al.
Publicado: (2022)

Orthosiphon stamineus Standardized Extract Reverses Streptozotocin-Induced Alzheimer’s Disease-Like Condition in a Rat Model
por: Retinasamy, Thaarvena, et al.
Publicado: (2020)

Regulation of gut microbiome by ketogenic diet in neurodegenerative diseases: A molecular crosstalk
por: Kaviyarasan, Shobana, et al.
Publicado: (2022)

Neuroinflammation: A Common Pathway in Alzheimer’s Disease and Epilepsy
por: Liew, Yee, et al.
Publicado: (2023)

The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review
por: Hui, Brendan Su Mee, et al.
Publicado: (2023)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Neuroprotective potency of mangiferin against 3-nitropropionic acid induced Huntington’s disease-like symptoms in rats: possible antioxidant and anti-inflammatory mechanisms
por: Lum, Pei Teng, et al.
Publicado: (2023)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
por: Silvestro, Serena, et al.
Publicado: (2022)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Implementation of World Health Organization behaviorally anchored rating scale and checklist utilization: promising results for LMICs
por: Khalid, Syed Yousaf, et al.
Publicado: (2023)

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
por: Abyadeh, Morteza, et al.
Publicado: (2021)

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
por: Geerts, Hugo, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Flotillin: A Promising Biomarker for Alzheimer’s Disease
por: Angelopoulou, Efthalia, et al.
Publicado: (2020)

Addressing an HIV cure in LMIC
por: Ismail, Sherazaan D., et al.
Publicado: (2021)

Advancing Tobacco Cessation in LMICs
por: Shankar, Abhishek, et al.
Publicado: (2022)

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
por: Dickson, Samuel P., et al.
Publicado: (2023)

Biobanking in LMIC settings for infectious diseases: Challenges and enablers()
por: Ezzat, Sameera, et al.
Publicado: (2022)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Neurosurgery abroad? Medical Graduate's perspective from LMIC
por: Farooq, Minaam, et al.
Publicado: (2023)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Racism and mental health in higher education: A challenge for LMICs
por: Dos Santos, Vagner, et al.
Publicado: (2019)

Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics
por: Padala, Sanjana P., et al.
Publicado: (2022)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjl83j4f398bm977r19nr1cuoc